SEARCH

SEARCH BY CITATION

References

  • 1
    Kleihues P,Louis DN,Scheithauer BW,Rorke LB,Reifenberger G,Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 21525, 2002; discussion 26–9.
  • 2
    Packer RJ. Brain tumors in children. Arch Neurol 1999; 56: 4215.
  • 3
    Russo VC,Gluckman PD,Feldman EL,Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005; 26: 91643.
  • 4
    Wang JY,Del Valle L,Gordon J,Rubini M,Romano G,Croul S,Peruzzi F,Khalili K,Reiss K. Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene 2001; 20: 385768.
  • 5
    Del Valle L,Enam S,Lassak A,Wang JY,Croul S,Khalili K,Reiss K. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 2002; 8: 182230.
  • 6
    Ogino S,Kubo S,Abdul-Karim FW,Cohen ML. Comparative immunohistochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors. Pediatr Dev Pathol 2001; 4: 2331.
  • 7
    van Doorn J,Gilhuis HJ,Koster JG,Wesseling P,Reddingius RE,Gresnigt MG,Bloemen RJ,van Muijen GN,van Buul-Offers SC. Differential patterns of insulin-like growth factor-I and -II mRNA expression in medulloblastoma. Neuropathol Appl Neurobiol 2004; 30: 50312.
  • 8
    Zumkeller W,Westphal M. The IGF/IGFBP system in CNS malignancy. Mol Pathol 2001; 54: 2279.
  • 9
    Samani AA,Yakar S,LeRoith D,Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 2047.
  • 10
    Bondy C,Werner H,Roberts CT,Jr.,LeRoith D. Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience 1992; 46: 90923.
  • 11
    Pomeroy SL,Tamayo P,Gaasenbeek M,Sturla LM,Angelo M,McLaughlin ME,Kim JY,Goumnerova LC,Black PM,Lau C,Allen JC,Zagzag D, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415: 43642.
  • 12
    Korshunov A,Neben K,Wrobel G,Tews B,Benner A,Hahn M,Golanov A,Lichter P. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003; 163: 17217.
  • 13
    Unterman TG,Glick RP,Waites GT,Bell SC. Production of insulin-like growth factor-binding proteins by human central nervous system tumors. Cancer Res 1991; 51: 30306.
  • 14
    Zumkeller W. IGFs and IGF-binding proteins as diagnostic markers and biological modulators in brain tumors. Expert Rev Mol Diagn 2002; 2: 4737.
  • 15
    Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004; 5: 20918.
  • 16
    Hargrave DR,Zacharoulis S. Pediatric CNS tumors: current treatment and future directions. Expert Rev Neurother 2007; 7: 102942.
  • 17
    Muller HL,Oh Y,Gargosky SE,Lehrnbecher T,Hintz RL,Rosenfeld RG. Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3). IGF and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. J Clin Endocrinol Metab 1993; 77: 11139.
  • 18
    Muller HL,Oh Y,Lehrnbecher T,Blum WF,Rosenfeld RG. Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 1994; 79: 42834.
  • 19
    de Bont JM,Kros JM,Passier MMCJ,Reddingius RE,Sillevis Smitt PAE,Luider TM,den Boer ML,Pieters R. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis Neuro-oncology, In press.
  • 20
    Stam RW,den Boer ML,Meijerink JP,Ebus ME,Peters GJ,Noordhuis P,Janka-Schaub GE,Armstrong SA,Korsmeyer SJ,Pieters R. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101: 12706.
  • 21
    Van Buul-Offers SC,Van Kleffens M,Koster JG,Lindenbergh-Kortleve DJ,Gresnigt MG,Drop SL,Hoogerbrugge CM,Bloemen RJ,Koedam JA,Van Neck JW. Human insulin-like growth factor (IGF) binding protein-1 inhibits IGF-I-stimulated body growth but stimulates growth of the kidney in snell dwarf mice. Endocrinology 2000; 141: 14939.
  • 22
    de Boer L,Hoogerbrugge CM,van Doorn J,van Buul-Offers SC,Karperien M,Wit JM. Plasma insulin-like growth factors (IGFs). IGF-Binding proteins (IGFBPs), acid-labile subunit (ALS) and. IGFBP-3 proteolysis in individuals with clinical characteristics of. Sotos syndrome. J Pediatr Endocrinol Metab 2004; 17: 61527.
  • 23
    van Doorn J,Hoogerbrugge CM,Koster JG,Bloemen RJ,Hoekman K,Mudde AH,van Buul-Offers SC. Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia. Clinical chemistry 2002; 48: 173950.
  • 24
    Rikken B,van Doorn J,Ringeling A,Van den Brande JL,Massa G,Wit JM. Plasma levels of insulin-like growth factor (IGF)-I. IGF-II and. IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 1998; 50: 16676.
  • 25
    Van Doorn J,Cornelissen AJ,Van Buul-Offers SC. Plasma levels of insulin-like growth factor binding protein-4 (IGFBP-4) under normal and pathological conditions. Clin Endocrinol (Oxf) 2001; 54: 65564.
  • 26
    Van Doorn J,Ringeling AM,Shmueli SS,Kuijpers MC,Hokken-Koelega AC,van Buul-Offers SC,Jansen M. Circulating levels of human insulin-like growth factor binding protein-6 (IGFBP-6) in health and disease as determined by radioimmunoassay. Clin Endocrinol (Oxf) 1999; 50: 6019.
  • 27
    Koedam JA,Hoogerbrugge CM,van Buul-Offers SC. Insulin-like growth factor-binding protein-3 protease activity in Snell normal and Pit-1 deficient dwarf mice. J Endocrinol 1998; 157: 295303.
  • 28
    Huber W,Von Heydebreck A,Sultmann H,Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18: S96104, 2002.
  • 29
    Benjamini Y,Hochberg Y. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J R Statist Soc B 1995; 57: 289300.
  • 30
    Hebert E. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep 2006; 26: 717.
  • 31
    Hahn H,Wojnowski L,Specht K,Kappler R,Calzada-Wack J,Potter D,Zimmer A,Muller U,Samson E,Quintanilla-Martinez L. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000; 275: 283414.
  • 32
    Hartmann W,Koch A,Brune H,Waha A,Schuller U,Dani I,Denkhaus D,Langmann W,Bode U,Wiestler OD,Schilling K,Pietsch T. Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol 2005; 166: 115362.
  • 33
    Rao G,Pedone CA,Valle LD,Reiss K,Holland EC,Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 2004; 23: 615662.
  • 34
    Elmlinger MW,Deininger MH,Schuett BS,Meyermann R,Duffner F,Grote EH,Ranke MB. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 2001; 142: 16528.
  • 35
    Wang H,Wang H,Zhang W,Fuller GN. Overexpression of IGFBP5, but not IGFBP3, correlates with the histologic grade of human diffuse glioma: a tissue microarray and immunohistochemical study. Technol Cancer Res Treat 2006; 5: 1959.
  • 36
    Fukushima T,Tezuka T,Shimomura T,Nakano S,Kataoka H. Silencing of insulin-like growth factor binding protein-2 (IGFBP-2) in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 2007; 282: 1863444.
  • 37
    Wang H,Wang H,Shen W,Huang H,Hu L,Ramdas L,Zhou YH,Liao WS,Fuller GN,Zhang W. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 2003; 63: 431521.
  • 38
    Boon K,Edwards JB,Siu IM,Olschner D,Eberhart CG,Marra MA,Strausberg RL,Riggins GJ. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 2003; 22: 768794.
  • 39
    Beattie J,Allan GJ,Lochrie JD,Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 2006; 395: 119.
  • 40
    Johnson SK,Dennis RA,Barone GW,Lamps LW,Haun RS. Differential expression of insulin-like growth factor binding protein-5 in pancreatic adenocarcinomas: identification using DNA microarray. Mol Carcinog 2006; 45: 81427.
  • 41
    Miyake H,Pollak M,Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000; 60: 305864.
  • 42
    Nordqvist AC,Mathiesen T. Expression of IGF-II. IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness. J Neurooncol 2002; 57: 1926.
  • 43
    Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001; 54: 1458.
  • 44
    Ricort JM,Binoux M. Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells. Biochem Biophys Res Commun 2004; 314: 10449.
  • 45
    Xi Y,Nakajima G,Hamil T,Fodstad O,Riker A,Ju J. Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Mol Cancer Ther 2006; 5: 307884.
  • 46
    Buckbinder L,Talbott R,Velasco-Miguel S,Takenaka I,Faha B,Seizinger BR,Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 6469.
  • 47
    Yi HK,Kim SY,Hwang PH,Kim CY,Yang DH,Oh Y,Lee DY. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 2005; 330: 7607.
  • 48
    Chang YS,Wang L,Liu D,Mao L,Hong WK,Khuri FR,Lee HY. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002; 8: 366975.
  • 49
    How HK,Yeoh A,Quah TC,Oh Y,Rosenfeld RG,Lee KO. Insulin-like growth factor binding proteins (IGFBPs) and IGFBP-related protein 1-levels in cerebrospinal fluid of children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1999; 84: 12837.
  • 50
    Pirttila T,Vanhatalo S,Turpeinen U,Riikonen R. Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS. Acta Neurol Scand 2004; 109: 33741.
  • 51
    Wilczak N,Schaaf M,Bredewold R,Streefland C,Teelken A,De Keyser J. Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis. Neurosci Lett 1998; 257: 16870.
  • 52
    Holly J,Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology 2006; 83: 15460.
  • 53
    Lalou C,Lassarre C,Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996; 137: 320612.
  • 54
    Angelloz-Nicoud P,Lalou C,Binoux M. Prostate carcinoma (PC-3) cell proliferation is stimulated by the 22–25-kDa proteolytic fragment (1–160) and inhibited by the 16-kDa fragment (1–95) of recombinant human insulin-like growth factor binding protein-3. Growth Horm IGF Res 1998; 8: 715.